INHIBRX, INC. INBX 深 滬
已收盤 10-24 16:00:00 美东时间
57.29
+28.930
+102.01%
華盛通- 最 高60.20
- 今 開49.13
- 成交量 607.70万股
- 最 低 46.01
- 昨 收 28.36
- 總市值 8.30亿
- 52周最高 60.20
- 市盈率 靜 0.49
- 換手率 41.95%
- 52周最低 10.805
- 委 比 14.29%
- 總股本 1448.54万
- 歷史最高 60.20
- 量 比 13.19
- 振 幅 50.04%
- 歷史最低 7.67
- 每 手 1
- 風險率 6.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | Wellgistics Health涨185.4%；INHIBRX涨102%
Wellgistics Health涨185.4%；INHIBRX涨102.0%；Genenta Science S.p.A.涨92.0%
10-25 16:28
Why Did Vivakor Shares Jump 40% In Pre-Market?
Vivakor shares jumped 38% in pre-market trading Friday following the announcement of a $40 million commodity credit facility.
10-24 16:43
Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?
Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 trial results for its cancer drug Ozekibart.
10-24 15:05
赛诺菲宣布efdoralprin alfa在全球ElevAATe II期研究中取得积极结果
10月22日，赛诺菲宣布其研发的efdoralprin alfa（SAR447537，前称INBRX-101）在全球ElevAATe II期研究中取得了积极结果...
10-23 17:07
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Ventyx Biosciences (NASDAQ:VTYX) shares rose 51.0% to $5.83 during Wedn...
10-23 05:06
Inhibrx Biosciences To Webcast ChonDRAgon Study Results For Ozekibart In Chondrosarcoma On October 23
– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT –SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical
10-23 04:02
快讯 | Inhibrx将举办网络直播，介绍其注册性试验中Ozekibart（Inbrx-109）在软骨肉瘤中的主要结果，并提供结直肠癌和尤文肉瘤扩展队列的最新进展
Inhibrx to Host Webcast Presentation of Topline Results From Its Registrational...
10-23 04:01
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform
JMP Securities analyst Reni J. Benjamin reiterates Inhibrx Biosciences (NASDAQ:INBX) from Market Perform to Market Perform.
08-22 20:55
读懂IPO|科望医药6条研发管线尚未商业化，企业称账面资金可支撑后续研发
本文来源：时代商业研究院 作者：彭元重 来源|时代商业研究院 作者|彭元重 凭借着“18A”制度的政策支持，今年以来，已有12家未盈利的生物医药企业成...
07-29 22:15
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
Incannex Healthcare successfully canceled all remaining Series A Warrants, eliminating potential dilution and streamlining its capital structure. This move clears the way for upcoming Phase 2 clinical milestones, including the topline data from the RePOSA trial of IHL-42X for obstructive sleep apnea, expected in July 2025. The company highlights its commitment to disciplined capital management and long-term value creation for shareholders.
06-12 11:30
